David Baldwin, MD, FRCP, Nottingham University Hospitals, Nottingham, UK, describes the impact of the COVID-19 pandemic on lung cancer screening in the UK. While delays were seen in the UK’s Targeted Lung Health Check screening programme, a number of ongoing trials and pilot programs successfully continued to perform lung cancer screening throughout the pandemic, which Prof. Baldwin highlights as a remarkable achievement. As the UK moves away from large surges in COVID-19 cases, the Targeted Lung Health Check screening programme has resumed, thus allowing the early detection of lung cancer. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.